The company plans to announce Phase 1b interim data by mid-2026, and the TENACITY-01 study is expected to be completed by late 2028. This timing enables progression to Phase 2 evaluation following ...

Under the ongoing collaboration Remedy Cell’s personnel, along with Pluri’s Contract Development and Manufacturing Organization (“CDMO”) division (PluriCDMO™), have successfully completed the full ...

Using drugs that inhibit enzymes called CDK4/6 and CDK2 extends the G1 phase of the cell cycle and helps to slow the growth of drug-resistant breast cancer.

During Warfighter Exercise (WfX) 25-01, the phrase “set conditions” was frequently used to describe prerequisites for ...

The journey started with an enigma in the zebrafish embryo: some endothelial cells, actively involved in the initial stages ...

Researchers discovered that a long-misunderstood protein plays a key role in helping chromosomes latch onto the right “tracks” during cell division. Instead of acting like a motor, it works more like ...

Abstract: In the realm of industrial Internet of Things, the imperative for ultra-reliable and low-latency communication (URLLC) is underscored by the demand for up to 99.999% reliability and ...

Abstract: We demonstrate a phase-coherent transmission system supported by the transmission of a seed lightwave in a dedicated multi-core fiber (MCF) core used as a reference for parametric optical ...